RU2628690C2 - Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний - Google Patents

Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний Download PDF

Info

Publication number
RU2628690C2
RU2628690C2 RU2015147703A RU2015147703A RU2628690C2 RU 2628690 C2 RU2628690 C2 RU 2628690C2 RU 2015147703 A RU2015147703 A RU 2015147703A RU 2015147703 A RU2015147703 A RU 2015147703A RU 2628690 C2 RU2628690 C2 RU 2628690C2
Authority
RU
Russia
Prior art keywords
virus
influenza
protein
attenuated
attenuated influenza
Prior art date
Application number
RU2015147703A
Other languages
English (en)
Russian (ru)
Other versions
RU2015147703A (ru
Inventor
Андрей Юрьевич Егоров
Борис ФЕРКО
Артем Александрович КРОХИН
Юлия Романовна Романова
Original Assignee
Общество С Ограниченной Ответственностью 'Фарминтерпрайсез'
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2015147703A priority Critical patent/RU2628690C2/ru
Application filed by Общество С Ограниченной Ответственностью 'Фарминтерпрайсез' filed Critical Общество С Ограниченной Ответственностью 'Фарминтерпрайсез'
Priority to SG11201709122VA priority patent/SG11201709122VA/en
Priority to MX2017015462A priority patent/MX380393B/es
Priority to UAA201709223A priority patent/UA125333C2/uk
Priority to CU2018000035A priority patent/CU24580B1/es
Priority to MA043314A priority patent/MA43314A/fr
Priority to CA2991023A priority patent/CA2991023C/en
Priority to EP16862552.3A priority patent/EP3382010A4/en
Priority to HK18111180.7A priority patent/HK1251616B/xx
Priority to KR1020177036573A priority patent/KR102604877B1/ko
Priority to PCT/RU2016/050066 priority patent/WO2017078577A2/ru
Priority to CN201680033797.2A priority patent/CN108026515B/zh
Priority to US15/566,202 priority patent/US10392604B2/en
Priority to EA201792083A priority patent/EA037571B1/ru
Priority to AU2016350939A priority patent/AU2016350939B9/en
Priority to JP2017560329A priority patent/JP6692835B2/ja
Priority to BR112017025435-2A priority patent/BR112017025435B1/pt
Publication of RU2015147703A publication Critical patent/RU2015147703A/ru
Application granted granted Critical
Publication of RU2628690C2 publication Critical patent/RU2628690C2/ru
Priority to IL255259A priority patent/IL255259B/en
Priority to CL2018001201A priority patent/CL2018001201A1/es
Priority to ZA201803649A priority patent/ZA201803649B/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2015147703A 2015-11-06 2015-11-06 Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний RU2628690C2 (ru)

Priority Applications (20)

Application Number Priority Date Filing Date Title
RU2015147703A RU2628690C2 (ru) 2015-11-06 2015-11-06 Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
CN201680033797.2A CN108026515B (zh) 2015-11-06 2016-11-03 用于预防和/或治疗感染性疾病以及用于治疗肿瘤疾病的减毒流感病毒载体
UAA201709223A UA125333C2 (uk) 2015-11-06 2016-11-03 Атенуйований грипозний вектор для профілактики і/або лікування інфекційних захворювань, а також для лікування онкологічних захворювань
CU2018000035A CU24580B1 (es) 2015-11-06 2016-11-03 Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
MA043314A MA43314A (fr) 2015-11-06 2016-11-03 Vecteurs de grippe atténues utilisés pour la prophylaxie et/ou le traitement de maladies infectieuses ainsi que pour le traitement de maladies oncologiques
CA2991023A CA2991023C (en) 2015-11-06 2016-11-03 Attenuated influenza vectors used for the prevention and/or treatment of infectious diseases as well as for the treatment of oncological diseases
EP16862552.3A EP3382010A4 (en) 2015-11-06 2016-11-03 ATTENUATED INFLUENZA VECTORS FOR THE PREVENTION AND / OR TREATMENT OF INFECTION DISEASES AND FOR THE TREATMENT OF ONCOLOGICAL DISEASES
HK18111180.7A HK1251616B (en) 2015-11-06 2016-11-03 Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases
KR1020177036573A KR102604877B1 (ko) 2015-11-06 2016-11-03 감염성 질환의 예방 및/또는 치료와 종양학적 질환의 치료를 위한 약독화된 인플루엔자 벡터
EA201792083A EA037571B1 (ru) 2015-11-06 2016-11-03 Аттенуированный вирус гриппа а, аттенуированный грипозный вектор, фармацевтическая композиция и их применение для профилактики или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
SG11201709122VA SG11201709122VA (en) 2015-11-06 2016-11-03 Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases
MX2017015462A MX380393B (es) 2015-11-06 2016-11-03 Vectores atenuados de influenza para la prevencion y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncologicas.
PCT/RU2016/050066 WO2017078577A2 (ru) 2015-11-06 2016-11-03 Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
AU2016350939A AU2016350939B9 (en) 2015-11-06 2016-11-03 Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases
JP2017560329A JP6692835B2 (ja) 2015-11-06 2016-11-03 感染性疾患の予防及び／又は処置並びに腫瘍性疾患の処置のための弱毒化インフルエンザベクター
BR112017025435-2A BR112017025435B1 (pt) 2015-11-06 2016-11-03 Vírus influenza a atenuado, vetores do vírus influenza e seus usos, composições imunogênicas e farmacêuticas, e vacinas contra influenza
US15/566,202 US10392604B2 (en) 2015-11-06 2016-11-03 Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases
IL255259A IL255259B (en) 2015-11-06 2017-10-25 Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases
CL2018001201A CL2018001201A1 (es) 2015-11-06 2018-05-03 Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas.
ZA201803649A ZA201803649B (en) 2015-11-06 2018-05-31 Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2015147703A RU2628690C2 (ru) 2015-11-06 2015-11-06 Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний

Publications (2)

Publication Number Publication Date
RU2015147703A RU2015147703A (ru) 2017-05-16
RU2628690C2 true RU2628690C2 (ru) 2017-08-21

Family

ID=58662984

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015147703A RU2628690C2 (ru) 2015-11-06 2015-11-06 Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний

Country Status (15)

Country Link
US (1) US10392604B2 (enExample)
EP (1) EP3382010A4 (enExample)
JP (1) JP6692835B2 (enExample)
KR (1) KR102604877B1 (enExample)
CN (1) CN108026515B (enExample)
AU (1) AU2016350939B9 (enExample)
CA (1) CA2991023C (enExample)
CU (1) CU24580B1 (enExample)
IL (1) IL255259B (enExample)
MA (1) MA43314A (enExample)
MX (1) MX380393B (enExample)
RU (1) RU2628690C2 (enExample)
SG (1) SG11201709122VA (enExample)
UA (1) UA125333C2 (enExample)
WO (1) WO2017078577A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2726106C1 (ru) * 2019-07-18 2020-07-09 федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) Рекомбинантный штамм вируса гриппа A/PR8-NS124-TB10.4-2A-HspX и способ специфической профилактики туберкулеза легких с использованием вакцины мукозального применения на его основе

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018217139A1 (ru) * 2017-05-26 2018-11-29 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Новые ингибиторы глутаминилциклаз и их применение для лечения различных заболеваний
AU2018392799A1 (en) 2017-12-22 2020-05-28 Codagenix, Inc. Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
CA3091508A1 (en) 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses
WO2020051766A1 (zh) 2018-09-11 2020-03-19 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
KR102370100B1 (ko) * 2019-02-15 2022-03-07 아이디바이오 주식회사 이종 인플루엔자 a 바이러스에 대한 면역/치료반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 유전자 전달체 및 치료백신
AU2021342299A1 (en) * 2020-09-11 2023-04-13 The United States Of America, As Represented By The Secretary Of Agriculture Compositions and methods of use thereof for prevention and treatment of influenza infections
AU2021378792A1 (en) * 2020-11-11 2023-05-04 California Institute Of Technology Multivalent carriers and related vaccine compositions
CN113430178B (zh) * 2021-06-21 2022-10-11 武汉大学 一种表达ii型单纯疱疹病毒蛋白的重组流感病毒株及其制备方法与应用
WO2025041889A1 (ko) * 2023-08-24 2025-02-27 성신여자대학교 연구산학협력단 외래 항원을 발현하는 재조합 인플루엔자 바이러스 벡터 및 이를 포함하는 백신 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800288B2 (en) * 2000-03-02 2004-10-05 Polymun Scientific Immunbiologische Forschung Gmbh Recombinant influenza A viruses
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
US20090053264A1 (en) * 1998-06-12 2009-02-26 Peter Palese Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
EA018174B1 (ru) * 2007-06-27 2013-06-28 Авир Грин Хилз Байотекнолоджи Рисерч Дивелопмент Трейд Аг Вирус гриппа с нарушенной репликацией для экспрессии гетерологичных последовательностей

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468544B1 (en) * 1998-06-12 2002-10-22 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses
US7709190B2 (en) * 2005-12-02 2010-05-04 Board Of Regents, The University Of Texas System Influenza A virus vaccines and inhibitors
EP2072058A1 (en) * 2007-12-21 2009-06-24 Avir Green Hills Biotechnology Research Development Trade Ag Modified influenza virus
WO2011014504A1 (en) * 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
CA2805505C (en) * 2009-07-30 2021-08-03 Mount Sinai School Of Medecine Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof
WO2011130652A2 (en) * 2010-04-15 2011-10-20 George Baer Compositions and methods for vaccinating humans and animals against enveloped viruses
JP2013531496A (ja) * 2010-06-06 2013-08-08 モウント シナイ スクール オフ メディシネ 組換えｒｎａウイルス及びその使用
CN103282375B (zh) * 2010-12-02 2017-01-11 比奥诺尔免疫有限公司 肽支架设计
EP2708552A1 (en) * 2012-09-12 2014-03-19 Medizinische Universität Wien Influenza virus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053264A1 (en) * 1998-06-12 2009-02-26 Peter Palese Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
US6800288B2 (en) * 2000-03-02 2004-10-05 Polymun Scientific Immunbiologische Forschung Gmbh Recombinant influenza A viruses
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
EA018174B1 (ru) * 2007-06-27 2013-06-28 Авир Грин Хилз Байотекнолоджи Рисерч Дивелопмент Трейд Аг Вирус гриппа с нарушенной репликацией для экспрессии гетерологичных последовательностей

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BORIS FERKO et al., Hyperattenuated Recombinant Influenza A Virus Nonstructural-Protein-Encoding Vectors Induce Human Immunodeficiency Virus Type 1 Nef-Specific Systemic and Mucosal Immune Responses in Mice, JOURNAL OF VIROLOGY, Oct. 2001, Vol.75, No.19, p. 8899-8908. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2726106C1 (ru) * 2019-07-18 2020-07-09 федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) Рекомбинантный штамм вируса гриппа A/PR8-NS124-TB10.4-2A-HspX и способ специфической профилактики туберкулеза легких с использованием вакцины мукозального применения на его основе

Also Published As

Publication number Publication date
AU2016350939B2 (en) 2021-07-08
WO2017078577A3 (ru) 2017-06-29
BR112017025435A8 (pt) 2019-08-20
AU2016350939B9 (en) 2021-07-22
MX380393B (es) 2025-03-12
MA43314A (fr) 2018-10-03
IL255259A (en) 2018-04-30
JP6692835B2 (ja) 2020-05-13
SG11201709122VA (en) 2017-12-28
AU2016350939A1 (en) 2017-11-23
BR112017025435A2 (pt) 2018-09-11
AU2016350939A2 (en) 2018-02-08
CA2991023A1 (en) 2017-05-11
US20180245052A1 (en) 2018-08-30
EP3382010A2 (en) 2018-10-03
US10392604B2 (en) 2019-08-27
WO2017078577A2 (ru) 2017-05-11
UA125333C2 (uk) 2022-02-23
CN108026515A (zh) 2018-05-11
JP2018531578A (ja) 2018-11-01
HK1251616A1 (zh) 2019-02-01
CN108026515B (zh) 2022-03-11
MX2017015462A (es) 2018-03-07
KR20180067464A (ko) 2018-06-20
CU24580B1 (es) 2022-02-04
EP3382010A4 (en) 2019-03-27
CU20180035A7 (es) 2018-07-05
IL255259B (en) 2020-03-31
CA2991023C (en) 2025-05-13
RU2015147703A (ru) 2017-05-16
KR102604877B1 (ko) 2023-11-23

Similar Documents

Publication Publication Date Title
RU2628690C2 (ru) Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
JP6870017B2 (ja) インフルエンザウイルス変異体およびその使用
Liu et al. Oral vaccination with a liposome‐encapsulated influenza DNA vaccine protects mice against respiratory challenge infection
Sylte et al. Influenza neuraminidase as a vaccine antigen
US10793834B2 (en) Live-attenuated virus and methods of production and use
US8597661B2 (en) Neuraminidase-deficient live influenza vaccines
CN101903043B (zh) 经过修饰的流感病毒
Liniger et al. MDA5 can be exploited as efficacious genetic adjuvant for DNA vaccination against lethal H5N1 influenza virus infection in chickens
JP2008522621A (ja) 世界的に流行するトリインフルエンザに対して迅速に応答するためのワクチン
Park et al. Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice
Park et al. Broad cross protection by recombinant live attenuated influenza H3N2 seasonal virus expressing conserved M2 extracellular domain in a chimeric hemagglutinin
Haque et al. Confronting potential influenza A (H5N1) pandemic with better vaccines
Martinez-Sobrido et al. AGL2017-82570-RReverse genetics approaches for the development of new vaccines against influenza A virus infections
RU2556833C2 (ru) Аттенуированный холодоадаптированный штамм вируса гриппа а/рr/8/59/m2 (h1n1), предназначенный для получения вакцинных штаммов вируса гриппа в качестве донора аттенуации, вакцинные штаммы вируса гриппа а/59/м2/калифорния/66/2211 (н2n2) и а/59/м2/токио/67/22111 (н2n2)
Luo et al. The virus-induced signaling adaptor molecule enhances DNA-raised immune protection against H5N1 influenza virus infection in mice
US20230295582A1 (en) Influenza virus backbone
US12447204B2 (en) Prime-boost influenza vaccine
EA037571B1 (ru) Аттенуированный вирус гриппа а, аттенуированный грипозный вектор, фармацевтическая композиция и их применение для профилактики или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
CN115103905B (zh) 表达α-1,3-半乳糖基转移酶的重组病毒及其用途
RU2660562C2 (ru) Аттенуированный гриппозный вектор и мукозальная универсальная гриппозная вакцина на его основе
HK1251616B (en) Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases
BR112017025435B1 (pt) Vírus influenza a atenuado, vetores do vírus influenza e seus usos, composições imunogênicas e farmacêuticas, e vacinas contra influenza
Cardenas-Garcia et al. FluB-RAM and FluB-RANS: Genome Rearrangement as Safe and Efficacious Live Attenuated Influenza B Virus Vaccines. Vaccines 2021, 9, 897
Parker Effect of a Codon Optimized DNA Prime on Induction of Anti-Influenza Protective Antibodies
Olszewska et al. VACCINATIONS| Viral

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20171201